Dialyse aktuell 2010; 14(7): 404-406
DOI: 10.1055/s-0030-1267325
Forum der Industrie

© Georg Thieme Verlag KG Stuttgart ˙ New York

ERA-EDTA-Nachlese – Hyperphosphatämie: neue Erkenntnisse, neue Ansatzpunkte

Further Information

Publication History

Publication Date:
27 September 2010 (online)

Also available at
 

Seit Jahren sind die Auswirkungen der Hyperphosphatämie bei chronisch nierenkranken Patienten bekannt: Hohe Phosphatwerte beschleunigen die Gefäßverkalkung und korrelieren mit einer höheren Mortalität [1]. Die Phosphatkontrolle gilt daher als ein wichtiger Grundpfeiler der Therapie niereninsuffizienter Patienten. Auf dem XLVII. ERA-EDTA/II. DGfN-Kongress Ende Juni in München widmete sich ein Mittagssymposium von Genzyme dem Thema "Phosphatstörung bei chronisch nierenkranken Patienten". Unter dem Vorsitz von Prof. Jürgen Floege, Aachen, stellten international renommierte Experten neueste Forschungsergebnisse vor und legten neue Perspektiven in Diagnostik und Therapie der Hyperphosphatämie dar.

Literatur

  • 01 Block G A, Klassen P S, Lazarus J M, et al . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.  J Am Soc Nephrol. 2004;  15 2208-2218
    Google Scholar
  • 02 Gutiérrez O M, Mannstadt M , Isakova T , et al . Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis.  N Engl J Med. 2008;  6 584-592
    Google Scholar
  • 03 Parker B D, Schurger L J, Brandenburg V M, et al . The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study.  Ann Intern Med. 2010;  152 640-648
    Google Scholar
  • 04 Koiwa F , Kazama J J, Tokumoto A , et al . Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients.  Ther Apher Dial. 2005;  9 336-339
    Google Scholar
  • 05 Oliveira R B, Cancela A L, Graciolli F G, et al . Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?.  Clin J Am Soc Nephrol. 2010;  5 286-291
    Google Scholar
  • 06 Shroff R C, McNair R , Skepper J N, et al . Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification.  J Am Soc Nephrol. 2010;  21 103-112
    Google Scholar
  • 07 Walter A M, Wiederhold K , Bruns D , et al . Synaptobrevin N-terminally bound to syntaxin-SNAP-25 defines the primed vesicle state in regulated exocytosis.  J Cell Biol. 2010;  188 401-413
    Google Scholar
  • 08 Chertow G M, Burke S K, Raggi P . Treat to Goal Working Group . Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.  Kidney Int. 2002;  62 245-252
    Google Scholar
  • 09 Block G A, Spiegel D M, Ehrlich J , et al . Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis.  Kidney Int. 2005;  68 1815-1823
    Google Scholar
  • 10 Russo D , Miranda I , Ruocco C , et al . The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer.  Kidney Int. 2007;  72 1255-1261
    CrossrefGoogle Scholar
  • 11 Barreto D V, Barreto Fde C , de Carvalho A B, et al . Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study.  Nephron Clin Pract. 2008;  110 c273-283
    CrossrefGoogle Scholar
  • 12 Quinibi, et al . Am J Kidney Dis. 2008;  51 962-966
  • 13 Jamal S A, Fitchett D , Lok C E, et al . The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.   Nephrol Dial Transplant. 2009;  24 3168-3174
    CrossrefGoogle Scholar
  • 14 Levin A , Bakris G L, Molitch M , et al . Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.  Kidney Int. 2007;  71 31-38
    CrossrefGoogle Scholar
  • 15 Ketteler M , Rix M , Fan S , et al . Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.  Clin J Am Soc Nephrol. 2008;  3 1125-1130
    CrossrefGoogle Scholar
  • 16 Ferreira A , Frazão J M, Monier-Faugere M C, et al . Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients.  J Am Soc Nephrol. 2008;  19 405-412
    CrossrefGoogle Scholar
  • 17 Dhingra R , Sullivan L M, Fox C S, et al . Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.  Arch Intern Med. 2007;  167 879-885
    CrossrefGoogle Scholar
  • 18 Kestenbaum B , Sampson J N, Rudser K D, et al . Serum phosphate levels and mortality risk among people with chronic kidney disease.  J Am Soc Nephrol. 2005;  16 520-528
    CrossrefGoogle Scholar
  • 20 Watanabe R , Lemos M M, Manfredi S R, et al . Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up.  Clin J Am Soc Nephrol. 2010;  5 189-194
    CrossrefGoogle Scholar
  • 21 Caglar K , Yilmaz M I, Saglam M , et al . Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.  Clin J Am Soc Nephrol. 2008;  3 61-68
    CrossrefGoogle Scholar
  • 22 Brandenburg V M, Schlieper G , Heussen N , et al . Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.  Nephrol Dial Transplant. 2010;  25 2672-2679
    CrossrefGoogle Scholar
  • 23 Fan S , Ross C , Mitra S , et al . A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.  Nephrol Dial Transplant. 2009;  24 3794-3799
    CrossrefGoogle Scholar